EHA 2022 | Improving the management of patients with newly diagnosed AML presenting with hyperleukocytosis
Fadi Haddad, MD, MD Anderson Cancer Center, Houston, TX, discusses strategies to improve the management of patients with newly diagnosed acute myeloid leukemia (AML) presenting with hyperleukocytosis, commenting on the results of a study that evaluated factors associated with worse overall survival (OS) in these patients. Dr Haddad first describes the characteristics of the patients included in the study, and explains that old age, coagulopathy, and renal replacement therapy were associated with a higher risk of mortality, while the use of leukapheresis or the presence of leukostasis did not affect OS. Moving forwards, Dr Haddad provides some recommendations for the management of patients presenting with hyperleukocytosis. This interview took place at the European Hematology Association (EHA) Congress 2022 held in Vienna, Austria.
